Each year, the Tax Foundation honors state legislators, executives, and other individuals with its Outstanding Achievement in State Tax Reform award. As the name suggests, the honoree's accomplishments...
- The Tax Policy Blog
- More Corporate Tax Deals this Week
More Corporate Tax Deals this Week
Funny, they always seem to go one direction: out of the U.S. and away from the developed world’s highest corporate tax rate.
- Pfizer's got an estimated $70 billion in cash, much of which is parked overseas. An acquisition of London-based AstraZeneca would put that cash to work without bringing it back to the U.S., avoiding a gigantic tax bill for Pfizer.
- The opportunity to lower its corporate tax rate. SunTrust analyst John Boris points out Pfizer pays the highest tax rate—28 percent in 2013—of all of its peers.That compares to 17 percent to 18 percent for Bristol-Myers Squibb and about 20 percent for AstraZeneca, he said. Reincorporating in lower-taxed locales, like Ireland, has been a hot trend among drug companies in the last few years (see: Actavis/Warner-Chilcott andPerrigo/Elan), and Pfizer could be seeking a similar path.
- Cancer drugs. AstraZeneca's got a pipeline of experimental medicines in a field called immuno-oncology, which aims to harness the immune system to fight cancer, one of the most important fields of cancer drug development.
Bloomberg also reports that Canada-based Valeant Pharmaceuticals made an offer for California-based Allergan Inc., maker of Botox. Canada’s corporate tax rate is 26 percent, versus 39 percent in the U.S. The U.K. will soon lower their corporate tax rate to 20 percent.
Follow William McBride on Twitter
Get Email Updates from the Tax Foundation
We will never sell or share your information with third parties.
Join the Tax Foundation's fight for sound tax policy Go
About the Tax Policy Blog
The Tax Policy Blog is the official blog of the Tax Foundation, a non-partisan, non-profit research organization that has monitored tax policy at the federal, state and local levels since 1937. Our economists welcome your feedback. If you would like to send an e-mail to the author of a blog post, please click on that person's name to locate his or her e-mail address or visit our staff page here.